Diakine Drug Conjugate (Autoimmune)

Diakine Drug Conjugate (Autoimmune) is a preclinical-stage therapeutic candidate being developed by DEKA Biosciences. It is a B cell-directed drug conjugate designed to selectively deplete or modulate autoreactive B cells, which play a central role in the pathogenesis of various autoimmune conditions. The drug is currently being investigated for the treatment of Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS), and Myasthenia Gravis (MG). As part of DEKA's proprietary Diakine platform, this candidate likely utilizes a cytokine-based scaffold or targeting moiety to deliver a therapeutic payload directly to B cells, aiming to restore immune homeostasis while minimizing off-target systemic toxicity.

Other names

B cell-directed drug conjugate